Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
UBS — EMMA KOLB
UBS barberer en tredjedel af kursmål for Teva
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
UBS: Tvivl om størrelse på mulig erstatning i Teva-sager - kan løbe op i større milliardbeløb
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Teva: 35% of senior management are women - Globes
Teva completes $3.2b acquisition of Auspex - Globes
Exclusive: UBS in talks with China Life for China asset management JV - sources - Headquarters Finance
Teva's collapse – Israel's biotech recovery - The Jerusalem Post
UBS applauds Teva for Auspex acquisition - Globes
Opioid Epidemic Settlement? What Purdue's Rumored Deal Means For Teva, Allergan | Investor's Business Daily
Teva Pharmaceutical Industries Stock Jumps on a Rare Bullish View | Barron's
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
Teva's Legal Overhang Triggers UBS Downgrade, Near-Halving Of Price Target
UBS raises Teva price target - Globes
UBS nedjusterer Teva Pharmaceuticals efter Kåre Schultz indgår forlig i USA
Storbank blåstempler Kåre Schultz' plan for Teva: Aktien er »for billig til at ignorere«
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
UBS Sees China Private Banking Revenue Pool Hitting $163 Billion - BNN Bloomberg
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Watch What You Need to Know: China, UBS, TEVA - Bloomberg
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Stock Picks to Buy, 13 Contrarian Names and Rationale for Each: UBS
